Related Experiment Videos
[Tumor markers in colorectal cancer]
S Gorgone1, A Alleruzzo, A G Rizzo
1Istituto di Chirurgia Generale, Università degli Studi di Messina.
Minerva Chirurgica
|August 1, 1992
Summary
Combined tumor markers like CEA, TPA, GICA, and CA 125 show limited use for early digestive tract cancer diagnosis. However, they are valuable for monitoring patients post-treatment.
Area of Science:
- Oncology
- Gastroenterology
- Biomarker Research
Background:
- Digestive tract cancers necessitate reliable diagnostic and monitoring tools.
- Tumor markers have been investigated for their potential in cancer management.
- Previous research explored various markers for gastrointestinal malignancies.
Purpose of the Study:
- To evaluate the combined utility of specific tumor markers in colorectal cancer.
- To assess the effectiveness of CEA, TPA, GICA, and CA 125 in early diagnosis.
- To determine the role of these markers in post-treatment patient monitoring.
Main Methods:
- Analysis of combined tumor marker levels (CEA, TPA, GICA, CA 125).
- Study population included patients with carcinoma of the colon-rectum.
- Evaluation of marker performance in early diagnosis versus post-treatment monitoring.
Main Results:
- Combined tumor markers demonstrated limited efficacy for early diagnosis of colorectal cancer.
- The investigated markers showed minimal value when used in association for initial detection.
- Significant utility was observed in monitoring patients after surgical, chemotherapeutic, or radiotherapeutic interventions.
Conclusions:
- The combination of CEA, TPA, GICA, and CA 125 is not recommended for the early detection of digestive tract cancers.
- These tumor markers are crucial for effective patient follow-up and management after cancer treatments.
- Further research may refine the application of these biomarkers in personalized cancer care.